Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial

Overview of attention for article published in Frontiers in Pharmacology, December 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (74th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

twitter: 6 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 1 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 8 X posts from 6 X users, with an upper bound of 6,093 followers.

RT @FrontPharmacol: New Research: Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial…

21 Dec 2023

Reply Repost Favourite

RT @FrontPharmacol: New Research: Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial…

21 Dec 2023

Reply Repost Favourite

New Research: Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial https://t.co/RA9mzKkWDk #pharmacology

21 Dec 2023

Reply Repost Favourite

RT @ATXA_Ireland: In first-in-human Phase 1 trials, @ATXA_Ireland's NTP42:KVA4 is safe and well tolerated, with favorable PK/PD characteris…

21 Dec 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.